A neuroimaging biomarker for striatal dysfunction in schizophrenia

被引：185

作者：

Li, Ang ^{[1
,2
,3
,4
]}

Zalesky, Andrew ^{[5
,6
,7
]}

Yue, Weihua ^{[8
,9
,10
]}

Howes, Oliver ^{[11
,12
]}

Yan, Hao ^{[8
,9
,10
]}

Liu, Yong ^{[1
,2
,3
,4
]}

Fan, Lingzhong ^{[1
,2
,3
,4
]}

Whitaker, Kirstie J. ^{[13
,14
]}

Xu, Kaibin ^{[1
,2
,3
]}

Rao, Guangxiang ^{[1
,2
,3
,4
]}

Li, Jin ^{[1
,2
,3
]}

Liu, Shu ^{[1
,2
,3
,4
]}

Wang, Meng ^{[1
,2
,3
,4
]}

Sun, Yuqing ^{[1
,2
,3
,4
]}

Song, Ming ^{[1
,2
,3
]}

Li, Peng ^{[8
,9
,10
]}

Chen, Jun ^{[1
,2
,3
]}

Chen, Yunchun ^{[15
]}

Wang, Huaning ^{[15
]}

Liu, Wenming ^{[15
]}

Li, Zhigang ^{[16
]}

Yang, Yongfeng ^{[17
,18
]}

Guo, Hua ^{[16
]}

Wan, Ping ^{[16
]}

Lv, Luxian ^{[17
,18
]}

Lu, Lin ^{[8
,9
,10
]}

Yan, Jun ^{[8
,9
,10
]}

Song, Yuqing ^{[8
,9
,10
]}

Wang, Huiling ^{[19
]}

Zhang, Hongxing ^{[17
,18
,20
]}

Wu, Huawang ^{[21
]}

Ning, Yuping ^{[21
]}

Du, Yuhui ^{[22
]}

Cheng, Yuqi ^{[23
]}

Xu, Jian ^{[23
]}

Xu, Xiufeng ^{[23
]}

Zhang, Dai ^{[8
,9
,10
,24
]}

Wang, Xiaoqun ^{[3
,4
,25
]}

Jiang, Tianzi ^{[1
,2
,3
,4
,26
,27
,28
]}

Liu, Bing ^{[1
,2
,3
,4
,26
]}

机构：

[1] Chinese Acad Sci, Brainnetome Ctr, Beijing, Peoples R China

[2] Chinese Acad Sci, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China

[3] Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China

[4] Chinese Acad Sci, Ctr Excellence Brain Sci & Intelligence Technol, Shanghai, Peoples R China

[5] Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia

[6] Melbourne Hlth, Melbourne, Vic, Australia

[7] Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia

[8] Peking Univ, Sixth Hosp, Inst Mental Hlth, Beijing, Peoples R China

[9] Peking Univ, Sixth Hosp, Minist Hlth, Key Lab Mental Hlth, Beijing, Peoples R China

[10] Peking Univ, Sixth Hosp, Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China

[11] Imperial Coll London, MRC London Inst Med Sci, Hammersmith Hosp, Psychiat Imaging Grp, London, England

[12] Kings Coll London, Inst Psychiat, London, England

[13] Univ Cambridge, Dept Psychiat, Cambridge, England

[14] British Lib, Alan Turing Inst, London, England

[15] Fourth Mil Med Univ, Xijing Hosp, Dept Psychiat, Xian, Peoples R China

[16] Zhumadian Psychiat Hosp, Zhumadian, Peoples R China

[17] Xinxiang Med Univ, Affiliated Hosp 2, Henan Mental Hosp, Dept Psychiat, Xinxiang, Henan, Peoples R China

[18] Xinxiang Med Univ, Int Joint Res Lab Psychiat & Neurosci Henan, Henan Key Lab Biol Psychiat, Xinxiang, Henan, Peoples R China

[19] Wuhan Univ, Renmin Hosp, Dept Psychiat, Wuhan, Peoples R China

[20] Xinxiang Med Univ, Dept Psychol, Xinxiang, Henan, Peoples R China

[21] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Peoples R China

[22] Shanxi Univ, Sch Comp & Informat Technol, Taiyuan, Peoples R China

[23] Kunming Med Univ, Affiliated Hosp 1, Dept Psychiat, Kunming, Yunnan, Peoples R China

[24] Peking Univ, McGovern Inst Brain Res, PKU IDG, Ctr Life Sci, Beijing, Peoples R China

[25] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing, Peoples R China

[26] Chinese Acad Sci, Innovat Acad Artificial Intelligence, Beijing, Peoples R China

[27] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Minist Educ, Key Lab Neuro Informat, Chengdu, Peoples R China

[28] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia

来源：

NATURE MEDICINE | 2020年 / 26卷 / 04期

关键词：

TREATMENT-RESISTANT SCHIZOPHRENIA; RESTING-STATE FMRI; FUNCTIONAL CONNECTIVITY; DOPAMINE HYPOTHESIS; GENE-EXPRESSION; NETWORK; PSYCHOSIS; RISK; DYSCONNECTIVITY; DISORDER;

D O I：

10.1038/s41591-020-0793-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia(1-5). We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-individual variation in baseline FSA scores was significantly associated with antipsychotic treatment response. FSA revealed a spectrum of severity in striatal dysfunction across neuropsychiatric disorders, where dysfunction was most severe in schizophrenia, milder in bipolar disorder, and indistinguishable from healthy individuals in depression, obsessive-compulsive disorder and attention-deficit hyperactivity disorder. Loci of striatal hyperactivity recapitulated the spatial distribution of dopaminergic function and the expression profiles of polygenic risk for schizophrenia. In conclusion, we have developed a new biomarker to index striatal dysfunction and established its utility in predicting antipsychotic treatment response, clinical stratification and elucidating striatal dysfunction in neuropsychiatric disorders. A new cross-validated neuroimaging biomarker that reflects striatal dysfunctioning can be used to distinguish patients with schizophrenia from healthy controls, and is associated with treatment response to antipsychotics.

引用

页码：558 / +

页数：20

共 59 条

[1] Deriving reproducible biomarkers from multi-site resting-state data: An Autism-based example [J].